Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds
Sponsor: Jetema Co., Ltd.
Summary
Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds
Official title: Multicenter, Randomized, Subject & Independent Evaluator-blind, Matched Pairs, Active-controlled, Non-inferiority, Pivotal Study to Evaluate the Efficacy and Safety of Injection With JTM104 as Compared to Juvederm® ULTRA PLUS XC in Temporary Correction of Moderate to Severe Nasolabial Folds
Key Details
Gender
All
Age Range
19 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-01-03
Completion Date
2027-01-31
Last Updated
2025-12-05
Healthy Volunteers
No
Conditions
Interventions
JTM104
JTM104 contains 22.8 mg/mL cross-linked hyaluronic acid, 1.2 mg/mL hyaluronic acid, and 3 mg/mL lidocaine. The product will be injected into the nasolabial folds, with a maximum volume of 1 mL per side.
Juvederm® ULTRA PLUS XC
Juvederm® ULTRA PLUS XC contains 22.8 mg/mL cross-linked hyaluronic acid, 1.2 mg/mL hyaluronic acid, and 3 mg/mL lidocaine. The product will be injected into the nasolabial folds, with a maximum volume of 1 mL per side.